Abby Hardy, Author at BioTuesdays

Executive Moves

ArcherDX names Mark Massaro as CFO

Mark Massaro Closely-held ArcherDX appointed research industry veteran, Mark Massaro, as its CFO. “Mark’s extensive knowledge of the diagnostics landscape, coupled with his more than 20 years of industry...

January 8, 2020

Developments

Apellis reports positive topline Phase 3 data in paroxysmal nocturnal hemoglobinuria

Apellis Pharmaceuticals (NASDAQ:APLS) reported positive topline results from its Phase 3 study evaluating pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Pegcetacoplan met the study’s...

January 7, 2020

Developments

Hepion paper published in Expert Opinion on Investigational Drugs

Hepion Pharmaceuticals’ (NASDAQ:HEPA) comprehensive review of studies on the role of cyclophilins in non-alcoholic steatohepatitis (NASH) and NASH-related liver disease has been published in peer-reviewed journal...

January 6, 2020

Developments

X4 Pharma starts Phase 1b trial of mavorixafor for Waldenström’s macroglobulinemia

X4 Pharmaceuticals (NASDAQ:XFOR) initiated a Phase 1b trial of mavorixafor in combination with ibrutinib, a Burton tyrosine kinase (BTK) inhibitor, for the treatment of Waldenström’s macroglobulinemia (WM). WM is a rare...

December 30, 2019

Developments

Lexicon Pharmaceuticals’ reports topline Phase 3 data for Type 2 diabetes drug

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported topline data from its Phase 3 study of sotagliflozin for the treatment of Type 2 diabetes (T2D). Sotagliflozin is an oral dual inhibitor of sodium-glucose co-transporter...

December 20, 2019

Developments

Aravive begins enrollment for Phase 2a kidney fibrosis trial

Aravive (NASDAQ:ARAV) has begun enrolling patients in its Phase 2a clinical trial of AVB-500 in patients with kidney fibrosis, specifically immunoglobulin A nephropathy (IgAN). IgAN occurs when an antibody called...

December 20, 2019

Developments

Arrowhead Pharma doses first patient in Phase 2 alpha-1 liver disease trial

Arrowhead Pharma (NASDAQ:ARWR) dosed the first patient in its Phase 2 clinical study of ARO-AAT for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated liver disease. AATD is a rare genetic disorder where...

December 20, 2019

Developments

Concert Pharmaceuticals completes alopecia areata trial

Concert Pharmaceuticals (NASDAQ:CNCE) completed its open-label trial comparing once-daily versus twice-daily dosing of CTP-543 in alopecia areata patients. Alopecia areata is an autoimmune disease that causes partial or...

December 20, 2019

Developments

Selecta completes enrollment in Phase 2 chronic refractory gout trial

Selecta Biosciences (NASDAQ:SELB) completed enrollment in its Phase 2 COMPARE trial of SEL-212 for the treatment of chronic refractory gout. SEL-212 is designed to sustain control of serum uric acid (SUA) levels in...

December 19, 2019

Developments

Aldeyra enrolls first patient in Phase 3 vitreoretinopathy trial

Aldeyra Therapeutics (NASDAQ:ALDX) enrolled the first patient in its Phase 3 GUARD trial of ADX-2191 for the prevention of proliferative vitreoretinopathy (PVR). PVR is an inflammatory disorder of the retina that leads...

December 19, 2019

Author - Abby Hardy

ArcherDX names Mark Massaro as CFO

Apellis reports positive topline Phase 3 data in paroxysmal nocturnal hemoglobinuria

Hepion paper published in Expert Opinion on Investigational Drugs

X4 Pharma starts Phase 1b trial of mavorixafor for Waldenström’s macroglobulinemia

Lexicon Pharmaceuticals’ reports topline Phase 3 data for Type 2 diabetes drug

Aravive begins enrollment for Phase 2a kidney fibrosis trial

Arrowhead Pharma doses first patient in Phase 2 alpha-1 liver disease trial

Concert Pharmaceuticals completes alopecia areata trial

Selecta completes enrollment in Phase 2 chronic refractory gout trial

Aldeyra enrolls first patient in Phase 3 vitreoretinopathy trial

Subscribe